What will the average number of measles cases be during Trump's term?

**Stage 1 — Blind analysis (ignore current market prices)**

*Summary of facts and reasoning:* 2025 produced roughly 1,900–2,000+ confirmed U.S. measles cases (reports later noting the U.S. passed 2,000). 2026 is proceeding even faster, with the U.S. surpassing 2,000 by mid‑year. Independent analyses suggest confirmed case counts substantially understate true incidence (a KFF Health News report cited a genetic-analysis-based multiplier of ~6.5x). Measles outbreaks in 2025–2026 have stressed clinical surveillance and response capacity and have been characterized in reporting as a possible "new normal" rather than an isolated blip.

If the four-year average is computed as (cases_2025 + cases_2026 + cases_2027 + cases_2028) / 4, the observed 2025 and 2026 totals alone (~2,000 + ~2,000 = ~4,000) already put the sum at or above 4,000. That means any non‑zero counts in 2027–2028 will keep a simple numeric threshold of 1,000 average well exceeded. Even a substantial fall in 2027–2028 (e.g., back to pre‑outbreak baselines of a few hundred per year) leaves the four‑year average far above 1,000 (example: 2000 + 2000 + 300 + 300 = 650 per year? — note: that example results in 650, which is below 1000; correct re‑calculation: (2000+2000+300+300)/4 = 650. Apologies — correct arithmetic shows two ~2,000 years plus two ~300 years gives 650 average, which would be below 1,000). Given that, I must nuance the numeric logic: the two high years (~2k each) produce a 4,000 subtotal; to have a 4‑year average >1,000 requires total >4,000 — i.e., 2027+2028 combined >0. So any positive 2027+2028 will push the average above exactly 1,000 only if the subtotal strictly exceeds 4,000. Because 2025+2026 around 4,000, even small positive totals in 2027–28 will push the mean just over 1,000. However, if 2025 and 2026 are slightly below 2,000 each (say 1,912 and 1,800) and 2027–28 are both very low (e.g., ~100 each), the average could hover near or below 1,000. Given uncertainty in exact published totals and definitions (confirmed vs. probable), this matters.

*Probabilistic judgement (blind):* Considering the reported >2,000 signals for both 2025 and 2026 (mid‑2026), the substantial underreporting multiplier possibility, ongoing transmission dynamics (low population immunity pockets, vaccine hesitancy, importation risk), and the limited capacity of public health to immediately revert to elimination‑era levels, I judge the probability that the 4‑year average exceeds 1,000 reported cases/year to be very high: **95%**. This reflects (a) the heavy weight of two large early years, (b) the likelihood of continued outbreaks in 2027–28 at non‑trivial levels unless extraordinary interventions occur, and (c) surveillance/systemic undercounting that biases confirmed counts downward (so true averages are higher).

**Arguments and uncertainties that reduce confidence:** A very aggressive, well‑funded national suppression campaign (mass vaccination drives targeted at outbreak hotspots), rapid normalization of clinic access, or natural epidemic burnout could bring 2027–28 down enough to pull the average close to or below 1,000 — though that requires large declines. There is also uncertainty about whether news reports conflate confirmed versus probable cases and whether final CDC reconciled totals will be materially different.

**Stage 2 — Market calibration (look at current market prices)**

The market currently prices 'Yes' at 0.34 (34%). My independent probability (95%) is sharply higher. Possible explanations for the market discount:

- *Different event definition/threshold:* Market traders may be interpreting the contract threshold differently (for example, requiring an average >2,000 or using a different denominator such as confirmed + probable definitions). If the contract's 'Yes' is set at a substantially higher threshold than 1,000, then a 34% price could be reasonable. Misreading of the contract by casual traders is common.

- *Misreading of front‑loaded risk:* Some traders may overweight the possibility of rapid rebound to pre‑outbreak baselines in 2027–28 and underweight the inertia of outbreaks and pockets of low immunity. They may assume two high years are temporary and that aggressive public health response will restore low levels quickly.

- *Liquidity and behavioral noise:* The market has nontrivial volume but can still be influenced by a few large positions, hedges, or risk‑off activity unrelated to epidemiology (e.g., traders using the market to hedge other political exposures). That can depress Yes price below epidemiologically warranted levels.

- *Surveillance and definitional uncertainty:* Traders may believe reported counts are volatile and that final confirmed totals will be revised downward, or they may think the CDC case definition or reporting cadence could change.

Taken together, absent a contract‑specific redefinition of 'Yes', the market appears to be underpricing the probability that the four‑year average is above 1,000 reported cases/year. If the contract actually uses a different threshold (e.g., >2,000), then my 95% is not appropriate and would need recalibration.

Actionable implication for traders: if the contract indeed uses a ~1,000/year threshold, buying 'Yes' at ~34c looks like a high-expected-value trade versus my 95% belief, after adjusting for standard risks (liquidity, threshold ambiguity). If the contract threshold is something else, do not trade until you confirm the exact definition.